Загрузка...
The predictive value of tumor mutation burden for immune checkpoint inhibitors therapy in non-small cell lung cancer is affected by patients’ age
High tumor mutation burden (TMB), which is associated with increased tumor immunogenicity, has been identified to predict improved response to immune checkpoint inhibitors (ICIs) therapy in non-small cell lung cancer (NSCLC). As host immunity is also significant to eliminate cancer cells, however, i...
Сохранить в:
| Опубликовано в: : | Biomark Res |
|---|---|
| Главные авторы: | , , , , , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
BioMed Central
2020
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7146978/ https://ncbi.nlm.nih.gov/pubmed/32308981 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40364-020-00188-2 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|